- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00000672
An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex
AMENDED: 8/29/90 Inclusion of asymptomatic patients with CD4 counts less than 200 cells/mm3. Standardization of baseline evaluation schedule to allow 14 days prior to study dosing. Reduction in frequency and intensity of follow-up evaluations. Standardization of study endpoints. Inclusion of toxicity scoring and management for amylase and triglyceride elevations. Clarification of concomitant medication use. Original design: To determine the effectiveness of didanosine (ddI) in patients with AIDS or advanced AIDS related complex (ARC) who have documented hematologic intolerance to zidovudine (AZT) therapy. To determine if the efficacy of ddI increases with increasing doses.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT. The major dose-limiting toxicities found in the Phase I studies have been pains in the feet and legs of 2 patients initially receiving 12 mg/kg/day and 12 patients receiving daily doses of 25.8 to 51.2 mg/kg; symptoms began 8 to 27 weeks after initiating ddI treatment. These neuropathy-like symptoms have generally not been associated with significant abnormalities in nerve conduction studies and patients have reported marked improvement in symptoms within 1 to 2 weeks of discontinuing ddI. Some patients have resumed ddI treatment at a reduced dose after resolution of their symptoms. Studies indicate that ddI remains active in the body for at least 12 hours. This indicates that benefits of ddI might be achieved with a low frequency of drug administration.
Studienübersicht
Detaillierte Beschreibung
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT. The major dose-limiting toxicities found in the Phase I studies have been pains in the feet and legs of 2 patients initially receiving 12 mg/kg/day and 12 patients receiving daily doses of 25.8 to 51.2 mg/kg; symptoms began 8 to 27 weeks after initiating ddI treatment. These neuropathy-like symptoms have generally not been associated with significant abnormalities in nerve conduction studies and patients have reported marked improvement in symptoms within 1 to 2 weeks of discontinuing ddI. Some patients have resumed ddI treatment at a reduced dose after resolution of their symptoms. Studies indicate that ddI remains active in the body for at least 12 hours. This indicates that benefits of ddI might be achieved with a low frequency of drug administration.
Patients are randomized to one of three ddI treatment groups; within each group, doses will be adjusted according to patient's weight at study entry. Stratification is by diagnosis of AIDS or AIDS related complex (ARC) and Medical Center. Data will be tabulated for the Data and Safety Monitoring Board at 3 month intervals.
Studientyp
Einschreibung
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
San Juan, Puerto Rico, 009275800
- San Juan Veterans Administration Med Ctr
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90033
- Los Angeles County - USC Med Ctr
-
Los Angeles, California, Vereinigte Staaten, 900481804
- Cedars Sinai / UCLA Med Ctr
-
Los Angeles, California, Vereinigte Staaten, 905022004
- Harbor - UCLA Med Ctr / UCLA School of Medicine
-
Los Angeles, California, Vereinigte Staaten, 900951752
- UCLA Med Ctr / Pediatric
-
Palo Alto, California, Vereinigte Staaten, 94304
- Palo Alto Veterans Adm Med Ctr / Stanford Univ
-
San Diego, California, Vereinigte Staaten, 921036325
- Univ of California / San Diego Treatment Ctr
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford Univ School of Medicine
-
Sylmar, California, Vereinigte Staaten, 91342
- Olive View Med Ctr
-
Sylmar, California, Vereinigte Staaten, 91342
- Sepulveda Veterans Adm Med Ctr / Olive View Med Ctr
-
Torrance, California, Vereinigte Staaten, 90502
- Harbor UCLA Med Ctr
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80262
- Univ of Colorado Health Sciences Ctr
-
Denver, Colorado, Vereinigte Staaten, 80262
- Mountain States Regional Hemophilia Ctr / Univ of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, Vereinigte Staaten, 20037
- George Washington Univ Med Ctr
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- G E Morey Jr
-
Miami, Florida, Vereinigte Staaten, 331361013
- Univ of Miami School of Medicine
-
Tampa, Florida, Vereinigte Staaten, 33612
- Univ of South Florida
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern Univ Med School
-
Hines, Illinois, Vereinigte Staaten, 60141
- Edward Hines Veterans Administration Hosp
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 462025250
- Indiana Univ Hosp
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Univ of Kansas School of Medicine
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Louisiana Comprehensive Hemophilia Care Ctr
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Louisiana State Univ Med Ctr / Tulane Med School
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane Univ School of Medicine
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins Hosp
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Harvard (Massachusetts Gen Hosp)
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston Med Ctr
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess - West Campus
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess Med Ctr
-
Springfield, Massachusetts, Vereinigte Staaten, 01199
- Baystate Med Ctr of Springfield
-
Worcester, Massachusetts, Vereinigte Staaten, 01605
- Med Ctr of Central Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Univ of Massachusetts Med Ctr
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Univ of Minnesota
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68105
- Nebraska Regional Hemophilia Ctr
-
-
New York
-
Bronx, New York, Vereinigte Staaten, 10461
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
-
Bronx, New York, Vereinigte Staaten, 10465
- Jack Weiler Hosp / Bronx Municipal Hosp
-
Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Med Ctr / Bronx Municipal Hosp
-
Bronx, New York, Vereinigte Staaten, 10468
- Bronx Veterans Administration / Mount Sinai Hosp
-
Buffalo, New York, Vereinigte Staaten, 14215
- SUNY / Erie County Med Ctr at Buffalo
-
Elmhurst, New York, Vereinigte Staaten, 11373
- City Hosp Ctr at Elmhurst / Mount Sinai Hosp
-
New York, New York, Vereinigte Staaten, 10003
- Beth Israel Med Ctr / Peter Krueger Clinic
-
New York, New York, Vereinigte Staaten, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, Vereinigte Staaten, 10021
- Mem Sloan - Kettering Cancer Ctr
-
New York, New York, Vereinigte Staaten, 10025
- Saint Luke's - Roosevelt Hosp Ctr
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Hemophilia Ctr / Mount Sinai Med Ctr
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Med Ctr
-
Rochester, New York, Vereinigte Staaten, 14642
- Univ of Rochester Medical Center
-
Stony Brook, New York, Vereinigte Staaten, 117948153
- SUNY - Stony Brook
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY / State Univ of New York
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 275997215
- Univ of North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Univ Med Ctr
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Bowman Gray School of Medicine / Wake Forest Univ
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 452670405
- Holmes Hosp / Univ of Cincinnati Med Ctr
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Univ Hosp of Cleveland / Case Western Reserve Univ
-
Columbus, Ohio, Vereinigte Staaten, 432101228
- Ohio State Univ Hosp Clinic
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 170330850
- Milton S Hershey Med Ctr
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Univ of Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- Hemophilia Ctr of Western PA / Univ of Pittsburgh
-
Pittsburgh, Pennsylvania, Vereinigte Staaten
- Univ of Pittsburgh Med School
-
-
South Carolina
-
West Columbia, South Carolina, Vereinigte Staaten, 29169
- Julio Arroyo
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr
-
-
Texas
-
Galveston, Texas, Vereinigte Staaten, 77550
- Univ TX Galveston Med Branch
-
Houston, Texas, Vereinigte Staaten, 77030
- Hermann Hosp / Univ Texas Health Science Ctr
-
Houston, Texas, Vereinigte Staaten, 77030
- Texas Children's Hosp / Baylor Univ
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- Univ of Utah School of Medicine
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Univ of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Great Lakes Hemophilia Foundation
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Concurrent Medication:
Required:
- Aerosolized pentamidine (300 mg every 4 weeks). In the event of physiological intolerance, alternative PCP prophylaxis may be trimethoprim/sulfamethoxazole 1 DS tab per day or dapsone 50 - 100 mg per day.
Allowed:
- Chronic suppressive treatment for toxoplasmosis, Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis, herpes simplex virus, cytomegalovirus, coccidioidomycosis, and histoplasmosis (absorption of ketoconazole or dapsone may be inhibited if given at the same time as the buffered solution of ddI, and should be taken 2 hours before or 2 hours after taking ddI; oral acidifying agents are not allowed). Isoniazid is permitted only if no acceptable alternative therapy is available. Metronidazole may be used for single courses not to exceed 14 days within consecutive 90 day intervals, the first of which begins at the initiation of the study. Erythropoietin for patients under the relevant treatment IND. Intravenous acyclovir for short courses of therapy.
Patients must:
- Have documented hematologic intolerance to zidovudine (AZT).
- Have the diagnosis of AIDS or advanced AIDS related complex (ARC).
- Have ended treatment for acute Pneumocystis carinii pneumonia (PCP) at least 2 weeks before study entry.
Have previous intolerance on at least two courses of AZT therapy (one of which must have been at daily doses of 500 mg of AZT or less).
- Be able to provide informed consent (and/or guardian as appropriate).
- Be available for follow-up for at least 6 months.
- Have baseline laboratory values as measured within 7 days before initial drug dosing.
- Allowed:
- Development of new opportunistic infections during the study - patients remain in the protocol.
Prior Medication:
Required:
- Prior use and intolerance to zidovudine (AZT).
- Allowed:
- Intralesional agents.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Presence of Kaposi's sarcoma (KS) with known or suspected visceral disease or where KS requires chemotherapy.
- Active AIDS defining opportunistic infections not specifically allowed.
- Intractable diarrhea.
- Stage 2 AIDS-dementia complex.
- History of intolerance to aerosolized pentamidine.
- Grade 2 neuropathy, based on the Neuropathy Targeted Symptom Questionnaire, or any moderate abnormality indicative of peripheral neuropathy, particularly impaired sensation of sharp pain, light touch, or vibration in the lower extremities, distal extremity weakness, or distal extremity hyporeflexia.
- Prior history of acute or chronic pancreatitis.
- History of seizures within past 2 years or currently requiring anticonvulsants for control.
- Any other clinical conditions or prior therapy which, in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements.
Concurrent Medication:
Excluded:
- Isoniazid (INH).
Patients with the following are excluded:
- Active AIDS-defining opportunistic infections not specifically allowed.
- Intractable diarrhea.
- AIDS-dementia complex = or > stage 2.
- History of intolerance to aerosolized pentamidine. Grade 2 neuropathy, based on the Neuropathy Targeted Symptom Questionnaire, or any moderate abnormality indicative of peripheral neuropathy, particularly impaired sensation of sharp pain, light touch, or vibration in the lower extremities, distal extremity weakness, or distal extremity hyporeflexia.
- Prior history of acute or chronic pancreatitis.
- History of seizures within past 2 years or currently requiring anticonvulsants for control.
- Any other clinical conditions or prior therapy which, in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements.
- Previous participation in any Phase I ddI study.
- Life expectancy < 6 months.
Prior Medication:
Excluded:
- Chronic therapy for cytomegalovirus infection with ganciclovir.
- ddI.
- d4T.
- ddC.
Excluded within 2 weeks of study entry:
- Zidovudine (AZT).
Excluded within 1 month of study entry:
- Therapy with any other antiretroviral drug or investigational agent not specifically allowed, including interferon and immunomodulating drugs.
- Ganciclovir.
- Neurotoxic drugs.
Excluded within 3 months of study entry:
- Ribavirin.
- Cytotoxic anticancer therapy.
Prior Treatment:
Excluded within 2 weeks of study randomization:
- Transfusion.
Active alcohol or drug abuse that is sufficient, in investigator's opinion, to prevent adequate compliance with study therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: JD Allan
- Studienstuhl: J Groopman
- Studienstuhl: M Seidlin
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994 Jul;32(7):716-31. doi: 10.1097/00005650-199407000-00005.
- Fiscus SA, Heggem-Snow A, Troiani L, Wallmark E, Folds JD, Sheff B, van der Horst CM. Transient high titers of HIV-1 in plasma and progression of disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):51-7.
- Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994 Aug 15;121(4):263-8. doi: 10.7326/0003-4819-121-4-199408150-00005.
- Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):169-74. doi: 10.1097/00042560-199510020-00009.
- Spino C, Kahn JO, Dolin R, Phair JP. Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):346-55. doi: 10.1097/00042560-199708150-00004.
- Reddy MM, Winger EE, Hargrove D, McHugh T, McKinley GF, Grieco MH. An improved method for monitoring efficacy of anti-retroviral therapy in HIV-infected individuals: a highly sensitive HIV p24 antigen assay. J Clin Lab Anal. 1992;6(3):125-9. doi: 10.1002/jcla.1860060305.
- Grieco MH, McKinley GF, Reddy MM. Effect of 2',3',-dideoxyinosine on HIV P24 antigen, beta2-microglobulin, neopterin,SCD8,SCD4,and SIL2R levels in patients with ARC or AIDS. Int Conf AIDS. 1991 Jun 16-21;7(2):199 (abstract no WB2069)
- Allan JD, DeGruttola V, Cross A, McLaren C, Seidlin M, Pettinelli C. An efficacy study of 2'3'-dideoxyinosine [ddI](BMY-40900) administered orally twice daily to zidovudine intolerant patients with HIV infection (ACTG 118). The AIDS Clinical Trials Group. Int Conf AIDS. 1993 Jun 6-11;9(1):67 (abstract no WS-B24-2)
- Sharma PL, Chatis PA, Dogon AL, Mayers DL, McCutchan FE, Page C, Crumpacker CS. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. Virology. 1996 Sep 15;223(2):365-9. doi: 10.1006/viro.1996.0488. Erratum In: Virology 1996 Nov 15;225(2):428.
Studienaufzeichnungsdaten
Haupttermine studieren
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- Langsame Viruserkrankungen
- HIV-Infektionen
- AIDS-bezogener Komplex
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antimetaboliten
- Didanosin
Andere Studien-ID-Nummern
- ACTG 118
- 070V1
- AI454-007
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Didanosin
-
Institut de Recherche pour le DeveloppementAbgeschlossen
-
Mansoura University Children HospitalAbgeschlossen
-
Tuberculosis Research Centre, IndiaIndian Council of Medical Research; National AIDS Control OrganisationUnbekanntTuberkulose | Infektionen mit dem Human Immunodeficiency VirusIndien
-
University of ParmaUniversity of Birmingham; Azienda Ospedaliero-Universitaria di Parma; Centro de...AbgeschlossenKardiometabolische Gesundheit | Individuelle Variabilität im (Poly)PhenolstoffwechselItalien
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers SquibbAbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
Bristol-Myers SquibbAbgeschlossen
-
Bristol-Myers SquibbAbgeschlossenHIV-InfektionenVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisSuspendiertHIV-InfektionenFrankreich
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers SquibbAbgeschlossen
-
Clinical Trial Agency of HIV Study GroupAbgeschlossen